OBJECTIVES: Sorafenib is a multi-tyrosine kinase inhibitor of Raf kinase, VEGFR, and PDGFR. Angiogenesis is important for growth and progression of SCLC. This trial was conducted to evaluate whether the combination of cisplatin and etoposide plus concurrent and sequential sorafenib could prolong survival in patients with previously untreated SCLC. METHODS: Previously untreated patients with extensive stage SCLC were treated with cisplatin and etoposide days 1, 2, 3 for four cycles, concurrent with sorafenib 200 mg orally bid starting day 1 cycle 1. Patients with no disease progression after four cycles continued sorafenib 400 mg orally bid as maintenance for maximum of 12 months. The primary endpoint was 1 year survival with response rate and safety as secondary endpoints. RESULTS: A total of 18 patients were enrolled with 17 evaluable patients. One patient had a complete response, seven patients had a partial response (overall response rate of 47 %) and one patient had stable disease. Overall median survival was 7.4 months and 1 year survival was 25 %. The most common treatment-related adverse events included fatigue, anorexia, rash, diarrhea, neutropenia and weight loss. Grade 5 GI bleeding, pulmonary hemorrhage and neutropenia occurred in one pt (6 %) each. Accrual was halted on the basis of safety profile as well as preliminary efficacy data. CONCLUSIONS: The combination of platinum based chemotherapy and sorafenib has significant toxicity at current dose levels and is associated with disappointing efficacy data.
OBJECTIVES:Sorafenib is a multi-tyrosine kinase inhibitor of Raf kinase, VEGFR, and PDGFR. Angiogenesis is important for growth and progression of SCLC. This trial was conducted to evaluate whether the combination of cisplatin and etoposide plus concurrent and sequential sorafenib could prolong survival in patients with previously untreated SCLC. METHODS: Previously untreated patients with extensive stage SCLC were treated with cisplatin and etoposide days 1, 2, 3 for four cycles, concurrent with sorafenib 200 mg orally bid starting day 1 cycle 1. Patients with no disease progression after four cycles continued sorafenib 400 mg orally bid as maintenance for maximum of 12 months. The primary endpoint was 1 year survival with response rate and safety as secondary endpoints. RESULTS: A total of 18 patients were enrolled with 17 evaluable patients. One patient had a complete response, seven patients had a partial response (overall response rate of 47 %) and one patient had stable disease. Overall median survival was 7.4 months and 1 year survival was 25 %. The most common treatment-related adverse events included fatigue, anorexia, rash, diarrhea, neutropenia and weight loss. Grade 5 GI bleeding, pulmonary hemorrhage and neutropenia occurred in one pt (6 %) each. Accrual was halted on the basis of safety profile as well as preliminary efficacy data. CONCLUSIONS: The combination of platinum based chemotherapy and sorafenib has significant toxicity at current dose levels and is associated with disappointing efficacy data.
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Barbara J Gitlitz; James Moon; Bonnie S Glisson; H Joachim Reimers; Martin J Bury; Justin D Floyd; Thomas K Schulz; P Kothai Sundaram; Christopher Ho; David R Gandara Journal: J Thorac Oncol Date: 2010-11 Impact factor: 15.609
Authors: José Baselga; José Getúlio Martins Segalla; Henri Roché; Auro Del Giglio; Hélio Pinczowski; Eva M Ciruelos; Sebastião Cabral Filho; Patricia Gómez; Brigitte Van Eyll; Begoña Bermejo; Antonio Llombart; Bernardo Garicochea; Miguel Ángel Climent Durán; Paulo Marcelo Gehm Hoff; Marc Espié; Andre Augusto Junior Gemeinder de Moraes; Ronaldo Albuquerque Ribeiro; Clarissa Mathias; Miguel Gil Gil; Belén Ojeda; Josefa Morales; Sunhee Kwon Ro; Shell Li; Frederico Costa Journal: J Clin Oncol Date: 2012-03-12 Impact factor: 44.544
Authors: David R Spigel; Peter M Townley; David M Waterhouse; Liang Fang; Ibrahim Adiguzel; Jane E Huang; David A Karlin; Leonardo Faoro; Frank A Scappaticci; Mark A Socinski Journal: J Clin Oncol Date: 2011-04-18 Impact factor: 44.544
Authors: Leora Horn; Suzanne E Dahlberg; Alan B Sandler; Afshin Dowlati; Dennis F Moore; John R Murren; Joan H Schiller Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: Andrew M Arnold; Lesley Seymour; Michael Smylie; Keyue Ding; Yee Ung; Brian Findlay; Christopher W Lee; Marina Djurfeldt; Marlo Whitehead; Peter Ellis; Glenwood Goss; Adrien Chan; Jacinta Meharchand; Yasmin Alam; Richard Gregg; Charles Butts; Peter Langmuir; Frances Shepherd Journal: J Clin Oncol Date: 2007-09-20 Impact factor: 44.544
Authors: Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail Journal: Cancer Res Date: 2004-10-01 Impact factor: 13.312
Authors: Mariacarmela Santarpia; Maria Grazia Daffinà; Niki Karachaliou; Maria González-Cao; Chiara Lazzari; Giuseppe Altavilla; Rafael Rosell Journal: Transl Lung Cancer Res Date: 2016-02
Authors: Neal E Ready; Herbert H Pang; Lin Gu; Gregory A Otterson; Sachdev P Thomas; Antonius A Miller; Maria Baggstrom; Gregory A Masters; Stephen L Graziano; Jeffrey Crawford; Jeffrey Bogart; Everett E Vokes Journal: J Clin Oncol Date: 2015-03-02 Impact factor: 44.544
Authors: Tiandong Kong; Lu Chen; Xiaoli Zhao; Fangfang Duan; Hanli Zhou; Lei Wang; Danna Liu Journal: Invest New Drugs Date: 2022-07-05 Impact factor: 3.651